JP2002506876A - 非晶質ポリマーを含む持続放出性組成物 - Google Patents

非晶質ポリマーを含む持続放出性組成物

Info

Publication number
JP2002506876A
JP2002506876A JP2000536736A JP2000536736A JP2002506876A JP 2002506876 A JP2002506876 A JP 2002506876A JP 2000536736 A JP2000536736 A JP 2000536736A JP 2000536736 A JP2000536736 A JP 2000536736A JP 2002506876 A JP2002506876 A JP 2002506876A
Authority
JP
Japan
Prior art keywords
composition
particles
drug
solvent
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000536736A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002506876A5 (fr
Inventor
ランドルフ，セオドア，ダブル．
マニング，マーク，シー．
フォルク，リチャード，エフ．
Original Assignee
ユニバーシティ テクノロジー コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ テクノロジー コーポレーション filed Critical ユニバーシティ テクノロジー コーポレーション
Publication of JP2002506876A publication Critical patent/JP2002506876A/ja
Publication of JP2002506876A5 publication Critical patent/JP2002506876A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2000536736A 1998-03-18 1999-03-18 非晶質ポリマーを含む持続放出性組成物 Pending JP2002506876A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7839098P 1998-03-18 1998-03-18
US60/078,390 1998-03-18
PCT/US1999/006198 WO1999047543A2 (fr) 1998-03-18 1999-03-18 Composition a liberation prolongee contenant un polymre amorphe

Publications (2)

Publication Number Publication Date
JP2002506876A true JP2002506876A (ja) 2002-03-05
JP2002506876A5 JP2002506876A5 (fr) 2006-02-02

Family

ID=22143753

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000536736A Pending JP2002506876A (ja) 1998-03-18 1999-03-18 非晶質ポリマーを含む持続放出性組成物

Country Status (5)

Country Link
EP (1) EP1073419A4 (fr)
JP (1) JP2002506876A (fr)
AU (1) AU3108299A (fr)
CA (1) CA2324254C (fr)
WO (1) WO1999047543A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006519202A (ja) * 2003-02-27 2006-08-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規苦味マスキング剤を含む医薬組成物
JP2007516259A (ja) * 2003-12-09 2007-06-21 メッドクリスタルフォームズ、エルエルシー 活性剤との混合相共結晶の調製方法
JP2011511088A (ja) * 2008-02-08 2011-04-07 キューピーエス リミテッド ライアビリティ カンパニー 薬物制御送達用の非ポリマー組成物
JP2016527308A (ja) * 2013-08-06 2016-09-08 ドン クック ファーマシューティカル カンパニー リミテッド エンテカビル微小球及びこれを含む非経口投与用医薬組成物
JP2017527593A (ja) * 2014-09-10 2017-09-21 ダブル ボンド ファーマシューティカルズ アクチボラグ 親水性薬物の標的化された送達

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2815540B1 (fr) † 2000-10-19 2005-06-10 Separex Sa Procede de fabrication de tres fines particules constituees d'un principe insere dans une molecule hote
JP2005514326A (ja) * 2001-07-10 2005-05-19 コリクサ コーポレイション ミクロスフェア中に封入されたタンパク質およびアジュバントを送達するための組成物および方法
GB0216780D0 (en) * 2002-07-19 2002-08-28 Bradford Particle Design Ltd Methods of particle formation
US8956602B2 (en) 2006-12-05 2015-02-17 Landec, Inc. Delivery of drugs
US8399007B2 (en) 2006-12-05 2013-03-19 Landec Corporation Method for formulating a controlled-release pharmaceutical formulation
US8114883B2 (en) 2007-12-04 2012-02-14 Landec Corporation Polymer formulations for delivery of bioactive materials
CN109069423A (zh) * 2016-03-07 2018-12-21 双键医药品股份公司 亲水性药物的肺部靶向递送

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582820A (en) * 1982-12-23 1986-04-15 Research Corporation Orally administered biologically active peptides and proteins
ATE37983T1 (de) * 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
AU5171293A (en) * 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
AU695207B2 (en) * 1995-03-28 1998-08-06 Fidia Farmaceutici S.P.A. Nanospheres comprising a biocompatible polysaccharide
WO1997038698A1 (fr) * 1996-04-18 1997-10-23 University Technology Corporation Procedes pour le traitement de troubles de l'oreille interne et moyenne

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006519202A (ja) * 2003-02-27 2006-08-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規苦味マスキング剤を含む医薬組成物
JP4694468B2 (ja) * 2003-02-27 2011-06-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規苦味マスキング剤を含む医薬組成物
JP2007516259A (ja) * 2003-12-09 2007-06-21 メッドクリスタルフォームズ、エルエルシー 活性剤との混合相共結晶の調製方法
US9682043B2 (en) 2003-12-09 2017-06-20 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
JP2011511088A (ja) * 2008-02-08 2011-04-07 キューピーエス リミテッド ライアビリティ カンパニー 薬物制御送達用の非ポリマー組成物
JP2016527308A (ja) * 2013-08-06 2016-09-08 ドン クック ファーマシューティカル カンパニー リミテッド エンテカビル微小球及びこれを含む非経口投与用医薬組成物
JP2017527593A (ja) * 2014-09-10 2017-09-21 ダブル ボンド ファーマシューティカルズ アクチボラグ 親水性薬物の標的化された送達
US10973772B2 (en) 2014-09-10 2021-04-13 Double Bond Pharmaceuticals Ab Targeted delivery of hydrophilic drugs

Also Published As

Publication number Publication date
WO1999047543A3 (fr) 1999-11-04
CA2324254C (fr) 2005-01-04
WO1999047543A2 (fr) 1999-09-23
CA2324254A1 (fr) 1999-09-23
EP1073419A4 (fr) 2009-03-25
AU3108299A (en) 1999-10-11
EP1073419A2 (fr) 2001-02-07

Similar Documents

Publication Publication Date Title
US6613358B2 (en) Sustained-release composition including amorphous polymer
US5981474A (en) Solubilization of pharmaceutical substances in an organic solvent and preparation of pharmaceutical powders using the same
JP5841708B2 (ja) 表面被覆微粒子の医薬組成物
ES2527286T3 (es) Microesferas de liberación sostenida y métodos de fabricación y uso de las mismas
ES2531679T3 (es) Composiciones para la administración de liberación controlada de péptidos
US6221397B1 (en) Surface cross-linked particles suitable for controlled delivery
EP2360188B1 (fr) Dérivé d'acide hyaluronique et sa composition pharmaceutique
Okamoto et al. Application of supercritical fluid to preparation of powders of high-molecular weight drugs for inhalation
US20050181059A1 (en) Nanoparticulate therapeutic biologically active agents
US20020032166A1 (en) Biocompatible cationic detergents and uses therefor
CN104105507A (zh) 增强粘膜渗透或减少炎症的纳米粒子
WO1994008599A9 (fr) Appariement d'ions de medicaments pour ameliorer l'efficacite et l'administration
WO1998010649A9 (fr) Detergents cationiques biocompatibles et leurs utilisations
NO180149B (no) Framgangsmåte for framstilling av en blanding for systemisk administrering gjennom slimhinner
CA2578175A1 (fr) Sels de dicetopiperazine, sels de dicetomorpholine ou sels de dicetodioxane permettant l'administration de medicaments
CN101094691A (zh) 载体
JP2002506876A (ja) 非晶質ポリマーを含む持続放出性組成物
JP2002522468A (ja) 核酸分子の保護された単一バイアル調製物、インライン混合によってそれを形成する方法、及び関連する生成物及び方法
TW201601742A (zh) 用於在活體中遞送ＲＮＡｉ觸發子至腫瘤細胞之聚結合物
CN101637454B (zh) 一种重组人骨形态发生蛋白-2壳聚糖微球及其制备方法
JP3346789B2 (ja) 持効性の生物分解性微粒子状物およびその調製方法
JP5491119B2 (ja) 薬物含有微粒子を含む医薬組成物およびその製造方法
US6551622B1 (en) Dry powder compositions
JP2004501188A (ja) インスリンの放出制御製剤及びその方法
CN104884078A (zh) 用于口服肽递送的脂肪酸酰化d-氨基酸

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090728

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100119